Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 101Leukemia 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Myelodysplastic Syndromes 83Leukemia, Lymphocytic, Chronic, B-Cell 78Lymphoma, Non-Hodgkin 76Multiple Myeloma 67Hodgkin Disease 67Lymphoma, Mantle-Cell 63Lymphoma 62Lymphoma, Large B-Cell, Diffuse 60Lymphoma, Follicular 59Leukemia, Myeloid, Chronic-Phase 57Lymphoma, B-Cell, Marginal Zone 53Burkitt Lymphoma 53Lymphoma, Large-Cell, Immunoblastic 49Leukemia, Myeloid, Accelerated Phase 48Congenital Abnormalities 48Myeloproliferative Disorders 46Leukemia, Myelomonocytic, Chronic 43Anemia, Refractory, with Excess of Blasts 41Graft vs Host Disease 37Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Blast Crisis 33Recurrence 32Dendritic Cell Sarcoma, Interdigitating 32Primary Myelofibrosis 27Lymphoma, T-Cell, Cutaneous 27Neoplasms, Plasma Cell 26Waldenstrom Macroglobulinemia 25

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Cyclosporine × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00009750 2013-09-20

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 1 Unknown
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡